Antiviral Therapies Market Statistics 2021: Growth, Forecast and Competitive Analysis

Anti-Viral Therapies Market

Antiviral therapies make use of drugs that inhibit the development of the virus causing infection. These drugs do not kill the target pathogen directly. These therapies are mostly particular against viral infections and do not cause side effects in the host’s body. Anti-viral therapies are widely used in treating HIV, herpes, hepatitis, influenza and other viral infections such as chicken pox and papilloma.

The global anti-viral therapies market size was valued at $38,316.5 million in 2018, and is projected to reach $46,213.4 million by 2026 registering a CAGR of 2.4% from 2019 to 2026.

The factors that drive the growth of the market include rise in prevalence of viral infections globally and presence of robust product pipeline with several pharmaceutical giants. Conversely, higher cost for treating these infections and shift in preference of the patients toward homeopathy and naturopathy are some of the key issues expected to hinder the antiviral therapies market growth. On the contrary, R&D for developing combination therapies to effectively eradicate the infections is anticipated to provide lucrative opportunities for the growth of the anti-viral therapies market during the forecast period.

Download Report Sample @ https://www.alliedmarketresearch.com/purchase-enquiry/6643

The global antiviral therapies market is segmented on the basis of application, type, mechanism of action, and region. Based on type, the branded drugs segment contributed to the largest share in 2018, accounting for more than half of the total share, and is estimated to maintain its dominant position during the forecast period. However, the generic drugs segment is expected to register the highest CAGR of 2.5% from 2019 to 2026.

Based on mechanism of action, the nucleotide polymerase inhibitor segment accounted for the largest share in 2018, holding nearly two-fifths of the total share, and is expected to maintain the largest share throughout the forecast period. However, the reverse transcriptase inhibitors segment is estimated to portray the highest CAGR of 3.1% during the forecast period.

Based on region, North America contributed the highest share, accounting for more than one-third of the total market share in 2018, and will maintain its dominance throughout the forecast period. However, Asia-Pacific is expected to grow at the highest CAGR of 2.8% from 2019 to 2026.

Inquire before buying @ https://www.alliedmarketresearch.com/request-sample/6643

The Major Key Players Are:

· F. Hoffmann-LaRoche Ltd.

· Gilead Sciences

· Glaxo Smith Kline

· Bristol-Myers-Squibb

· Abbott Laboratories

· Astra Zeneca plc

· Abb Vie Inc.

· Aurobindo Pharma Limited

· Johnson & Johnson

· Merck & Co.,Inc.

The other Key players Are:

· Schering-PloughCorporation

· Cipla

· DrReddy’s.

Key Findings Of The Study

· Nucleotide polymerase inhibitor segment occupied 38.44% share of the global anti-viral therapies market in 2018.

· By application, HIV segment is anticipated to grow with the highest CAGR throughout the forecast period.

· By type, the generic drugs segment accounted for 46.8% share of the market in 2018.

· Asia-Pacific is anticipated to grow at the 2.8% during the analysis period.

Access Full Report @ https://www.alliedmarketresearch.com/anti-viral-therapies-market-A06278

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.